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Background: The survival promoting peptide Y-P30 has a variety of neuritogenic and neuroprotective effects
in vitro and in vivo. In previous work we reported the expression of Y-P30/dermcidin in maternal peripheral blood
mononuclear cells (PBMCs) and the transport of the protein to the fetal brain. In this study we analyzed hormonal
regulation of Y-P30 in human immune cells and expression of Y-P30 in the placenta. We further studied the stability
and secretion of the Y-P30 peptide.
Results: We found indications that Y-P30 might be produced in human placenta. The Y-P30 mRNA was rarely
found in isolated human PBMCs and alpha-feto-protein, human chorionic gonadotropin as well as estradiol
combined with progesterone could not induce Y-P30 expression. Y-P30 was found to be extraordinarily stable;
therefore, contamination with the peptide and the Y-P30/Dermcidin precursor mRNA is a serious concern in
experiments looking at the expression of Y-P30/Dermcidin. In cultured cell lines and primary neurons we found
that Y-P30 could be released, but neuronal uptake of Y-P30 was not observed.
Conclusions: Our data suggest that a source of Y-P30 apart from eccrine glands might be the placenta. The
peptide can be secreted together with the signaling peptide and it might reach the fetal brain where it can exert
its neuritogenic functions by binding to neuronal membranes.
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The survival promoting peptide Y-P30 has neurite out-
growth promoting effects in vitro [1,2]. In addition potent
neuroprotective effects against various insults including
traumatic brain injury, oxidative stress, hypoxia and optic
nerve crush have been ascribed to the peptide [3-6]. The
underlying mechanisms for this broad spectrum of bio-
logical activities are still largely unclear. Cell migration
and neurite outgrowth promoting activities appear to
rely on binding of Y-P30 to syndecans and pleiotrophin
[2,7-9]. Other interactions have been reported for calre-
ticulin [4], HSP70 [10] and NCK [11] and it was specu-
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article, unless otherwise stated.effects of the peptide. Y-P30 is the N-terminal portion
of a larger propeptide precursor that encodes a second
bioactive peptide, dermcidin (Figure 1), which is se-
creted by human sweat glands and has been shown to
play an important role in antimicrobial defense [12].
The identity of peptide fragments cleaved from the
N-terminus of the precursor protein is not clear. The
sequence of Y-P30 overlaps with that of the proteolysis
inducing factor [13,14]. In contrast to Y-P30, PIF is gly-
cosylated and was originally identified as a factor that
induces cachexia in mice and cancer patients [13], al-
though this role in humans has been disputed [15].
Our previous work has suggested that Y-P30 could be a
blood-borne factor in rats which is produced by PBMCs
of the maternal immune system [1]. However, despite the
identification of several Y-P30/dermcidin peptides with
mass-spectroscopy in various mammals, the dermcidin
gene seems to be absent in the genome of non-primatetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic of the Y-P30/dermcidin precursor. SP: signal
peptide. PIF: proteolysis inducing factor.
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rodents raise questions regarding the source of the peptide.
In human, a prominent expression in eccrine sweat glands
is not disputed; further, some studies reported the Y-P30/
dermcidin precursor protein in human blood in acute
ischemic heart disease [18,19] and in placenta [20]. Other
studies found the Y-P30 mRNA in human brain [21] and
neural cell lines [3]. Moreover, dermcidin has been re-
ported a candidate oncogene in human cancer [21,22] and
to promote proliferation of mouse, rat and human tumor
cells [13,22-24], but see also [15]. In this study we aimed to
address open questions and conflicting results regarding
the expression, secretion and source of Y-P30.
Methods
cDNA constructs
cDNA constructs (see Figure 2) encoding the human Y-P30-
Dermcidin (DCD) precursor (aa 1–109), Y-P30-Dermcidin
precursor lacking the N-terminal signal peptide (aa
21–109), Y-P30 with (aa 1–49) and without (aa 21–49)
signal peptide were subcloned into the pEGFP-N1 vec-
tor (Clontech). pEGFP-N1 was used as a negative con-
trol. For bacterial expression, Y-P30 containing the signal
peptide (aa 1–49) was subcloned into a pTYB21 vector.
Expression and purification of Y-P30 via the Intein system
was performed according to manufacturer’s instructions
(Impact kit, NEB) and previously published protocols [25].
Fingerprint and in vitro stability assay
Probands were asked to keep washed and air-dried hands
for 30 min in a plastic bag and then to press the thumb
gently on a piece of nitrocellulose (BA85, Whatman). The
membranes were kept for up to 5 days at RT on a lab
shelve in a standard plastic cell culture plate. The staining
was not compromized after prolonged storage. For staining,the membrane was soaked in TBS, blocked with 4% BSA
in TBS, incubated overnight at 8°C in the primary anti-
bodies against DCD (H-91 rabbit anti-DCD, 1:50; Santa
Cruz) and Y-P30 (N20 goat anti-DCD N-terminal peptide,
1:50; Santa Cruz), washed in TBS with 0.05% Tween-20, in-
cubated with appropriate alkaline phosphatase-conjugated
secondaries for 1 h, followed by alkaline color reaction with
NBT-BCIP. Membranes were dried and photographed.
Y-P30 (aa 21–49) was synthesized as described previ-
ously [1]. For measuring stability of the peptide in vitro,
Y-P30 was diluted in PBS (2 μg/μl) and incubated at
room temperature over 24, 48 and 72 hours as well as 7
and 14 days. Additionally, the effect of different denatur-
ing agents (urea, 8 M; dithiothreitol (DTT), 50 mM and
100 mM; iodoacetamide, 50 mM) was studied with incu-
bation times of 2 and 12 hours. Thereafter, 4x sample
loading dye (containing 5% beta-mercaptoethanol and
8% SDS) was added to 1x final concentration, all samples
were boiled for 5 min at 95°C and subjected to SDS-
PAGE with subsequent immunoblotting using a rabbit
anti-Y-P30 antibody described previously [1,2].
Cleavage assay
Cleavage of the Y-P30-Dermcidin precursor in COS-7
cells (monkey) and HEK-293 T cells (human) was stud-
ied by transfecting cells with different Y-P30-Dermcidin-
GFP fusion constructs. Transfection of cells was done as
described previously [26]. Briefly, cells were seeded on
6-well plates supplemented with DMEM and used for
transfection before they reached confluence. Transfection
was performed using Lipofectamine (Invitrogen) accord-
ing to the supplier’s manual. 48 hours after transfection
the medium was collected. Cells were harvested in 1 x
PBS, washed and lysed in 10 mM Tris buffer. Proteins
samples from the medium and cell lysates were subjected
to SDS-PAGE and immunoblotting with an rabbit anti-Y-
P30 and mouse anti-GFP antibody.
ELISA test
To quantitatively assess the level Y-P30/dermcidin precur-
sor in placenta extract, plasma and serum from pregnant
women, an ELISA kit for dermcidin (Uscn Life Science)
was used according to the manufacturer’s protocol. Briefly,
placenta samples were homogenized in PBS and treated
with 0.5% (final concentration) Triton X-100. The Triton
X-100 extracts were used for ELISA. Plasma and serum
proteins were enriched by precipitation with 100% ethanol
at −20°C over 72 h, and precipitates were re-suspended in
PBS.
Y-P30 supplementation assay
Y-P30-GFP was produced by in vitro ligation of Y-P30 con-
taining the signal peptide and cys-GFP in the presence of
10 mM MESNA via thiol-mediated protein ligation. After
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Figure 2 Exocytosis and processing of the Y-P30/dermcidin precursor. (A) Schematic of the constructs employed. (B + C) GFP-fusion constructs
depicted in A were transfected into COS-7 and HEK-293 T cells. 24 hours after transfection the culture medium (supernatant) was collected
and precipitated with 100% acetone to increase protein concentration. Cells were washed, harvested and lysed (pellet). Both, cell pellet and
supernatant were analyzed by immunoblotting with anti-Y-P30 or anti-GFP antibodies. SP: signal peptide.
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buffer, aliquoted and stored at −80°C. Differentiated pri-
mary cortical neurons were supplemented with Y-P30-GFP
(10 μg/1 ml) for 24 h, then fixed and stained as described
below.Co-culture of primary neurons and HEK-293 T cells
Primary cortical neurons were plated on 18 mm coverslips
as described previously [27]. HEK-293 T cells were plated
on 6-well plates and transfected with the various Y-P30-
Dermcidin-GFP plasmids or empty GFP control plasmids
using the calcium phosphate method. 24 h after transfec-
tion, supplemented DMEM medium was removed and
HEK-293 T cells were gently re-suspended in 500 μl of neu-
robasal medium with antibiotics, glutamine and serum.
Then, 30 μl of HEK-293 T cell suspension was added to
DIV1 primary neurons. Cells were grown in co-culture for
the next 24 h, then fixed and stained as described below.Immunocytochemistry, laser scanning microscopy and
image analysis
Coverslips with cortical neurons supplemented with
Y-P30-GFP, or cortical neurons co-cultured with trans-
fected HEK-293 T cells were fixed with 4% PFA for
10 min at 37°C, extensively washed with PBS and im-
munostained for the neuronal marker MAP2 (1:1000;
mouse, Sigma) and Y-P30 (rabbit, 1:100) as described
before [28]. Fluorescence images were obtained on a TCS
SP5 II confocal laser scanning microscope (Leica,
Germany) using a 63x oil objective. Images were acquired
as z-stacks with 0,3 μm z-step. Maximum projections of
z-stack were created in the ImageJ program (ImageJ,
NIH).Sample collection
Human blood samples were obtained from non-pregnant
women or healthy pregnant women at all three trimesters.
PBMCs were isolated by density gradient centrifugation
and washed twice in PBS. Then, PBMCs were either used
freshly for hormonal stimulation or frozen as cell pellet
at −80°C for Y-P30/dermcidin expression analysis. Add-
itionally, placenta tissue samples were obtained from
patients either suffering from spontaneous abortions or
pre-eclampsia. Placenta samples from normal pregnant
women undergoing elective termination of pregnancy
during their first trimester (labeled as interuptio in the
Figures) or having normally progressing pregnancies
until birth (labeled as TERM in the Figures) were taken
as controls. Placental tissue was immediately snap fro-
zen and stored at −80°C. All women provided informed
consent and tissue sampling was approved by the Ethics
Board of the University of Magdeburg (study 28/08).
The characteristics of the patients included in the study
are shown in Table 1.Hormonal stimulation of PBMCs
5 × 106 PBMCs from non-pregnant women were first
cultured for 24 h in RPMI 1640 medium (Invitrogen,
Karlsruhe, Germany) supplemented with 100 ng/ml peni-
cillin/streptomycin and 3% of charcolized fetal bovine
serum (FBS) (Biochrom, Berlin, Germany) to reduce un-
desirable side effects due to hormonal contaminations
of FBS. Afterwards, the cells were stimulated for 1 h
with 50 μg/ml alpha-feto-protein (Antikoerper-Online,
Aachen, Germany), 100 IU/ml human chorionic
gonadotropin (Pregnyl, Organon, Netherlands), 10 ng/ml
progesterone (Sigma, Steinheim, Germany), 100 pg/ml es-
trogen (Sigma, Steinheim, Germany), or progesterone and
Table 1 Characteristics of Normal Pregnant (NP),
Spontaneous Abortion (SA) and Pre-Eclamptic (PE)
patients at different pregnancy stages
PBMCs Trimester Age Week of pregnancy
NP (n = 16) I 26,25 ± 7,30 10,19 ± 1,98
NP (n = 2) II 28,50 ± 0,50 18,5 ± 3,5
NP (n = 6) III 30,33 ± 3,64 30,33 ± 4,15
Placental tissue Trimester Age Week of pregnancy
NP (n = 8) I 32,75 ± 6,32 9,88 ± 1,17
SA (n = 12) I 33,18 ± 3,86 10,13 ± 3,28
NP (n = 12) III 30,55 ± 5,19 39,33 ± 1,11
PE (n = 8) III 35,50 ± 5,32 37,33 ± 1,25
Data are presented as mean plus standard deviation. No statistical differences
could be detected among groups.
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controls. After stimulation PBMCs were harvested, washed
twice in PBS and frozen as cell pellets for Y-P30/dermcidin
expression analysis by PCR.RNA isolation and cDNA synthesis
Total RNA was isolated from hormonal-treated and
non-treated PBMCs as well as from placenta tissue sam-
ples as described elsewhere [29] and converted into
cDNA for PCR analysis. Briefly, PBMCs and placental
tissue (100 mg) were resolved in 1 ml Trizol® Reagent
(Invitrogen, Darmstadt, Germany) and tissue samples were
further disaggregated using a homogenizer (Ultra Turrax
T8; Ika, Germany). The RNA was then extracted with
200 μl chloroform (Sigma, Steinheim, Germany), precipi-
tated with isopropanol (Roth, Karlsruhe, Germany), washed
with 80% ethanol (Otto Fischer, Magdeburg, Germany) and
finally re-suspended in RNAse-free water (Berlin Chemie,
Berlin, Germany). RNA concentration was determined by
reading ultraviolet absorbance at 260 nm.
To obtain cDNA, 2 μg of total RNA were diluted
in RNase-free water and added with oligo-dT primer
(Promega, Mannheim, Germany). After incubation at
75°C for 10 min, samples were placed on ice, and dNTP
(2.5 mM; Pharmacia, Freiburg, Germany), DNase I (2 U/ml;
Stratagene, Amsterdam, Netherlands) and RNase inhibi-
tor (40 U/ml; Promega, Mannheim, Germany) mixed in
reaction buffer were added. The reaction mix was incu-
bated for 30 min at 37°C and heated to 75°C for 5 min.
The addition of the reverse transcriptase (200 U/ml;
Amersham) and RNase inhibitor started the reverse
transcription. The reaction mix was incubated at 42°C
for 60 min followed by inactivation of the enzymes at
94°C for 5 min. cDNA was stored at −20°C until use.Nested polymerase chain reaction (PCR)
Nested PCRs intend to reduce non-specific primer bind-
ing and are carried out in two successive PCR runs, in-
volving two sets of primers. For the first PCR run, the
amplification reaction (24 μl) consisted of 2 μl cDNA,
5 μl 5x Green GoTaq® Reaction Buffer, 0.5 μl dNTP mix
(10 mM), 0.125 μl GoTaq® DNA polymerase (all from
Promega, Mannheim, Germany), 0.5 μl of the forward
primer (GGG AAT TCA TGA GGT TCA TGA CTC
TCC TCT), 0.5 μl of the reverse primer (ACG CGC
CGA CTC ACT ATA GTA CTG AGT CAA) and filled
up to 24 μl with double distilled water. No template
controls (NTCs) containing water instead of cDNA were
included. The Y-P30/dermcidin precursor cDNA was
used as a positive control. For the second PCR run, the
reaction mix (20 μl) contained 5 μl PCR product from
the first run, 5 μl 5x Green GoTaq® Reaction Buffer,
0.5 μl dNTP mix (10 mM), 0.1 μl GoTaq® DNA polymerase,
0.5 μl of the forward primer (AGC ATG AGG TTC ATG
ACT CTC), 0.5 μl of the reverse primer (CAC GCT TTC
TAG ATC TTC GAC) and double distilled water up to
20 μl. PCR reactions were performed as follows: initial de-
naturation step of 2 min at 95°C, followed by 45 sec at 95°C,
45 sec at 58°C (first run) or 56°C (second run) and
1 min at 72°C for 40 cycles. Additionally, the house-keeping
gene HPRT was amplified in all samples. Subsequently,
PCR products were sequenced. PCR products were visual-
ized by agarose gel electrophoresis (2% gel, 100 V for 2.5 h).
Quantitative (q) RT-Real-time PCR
For RT-PCR analysis, TaqMan (for the Y-P30/dermcidin
transcript) as well as SYBR® Green (for the syndecan-3
and −4 transcripts) technology were conducted using
an iQ™5 Multicolor Real-Time PCR detection system
(Bio-Rad, Munich, Germany). For Y-P30/dermcidin, amplifi-
cation reactions (13 μl) consisted of 1 μl of cDNA, 6.25 μl of
mastermix containing PCR buffer, dNTPs, MgCL2, and
Ampli-Taq DNA polymerase (Eurogentec, Berlin, Germany),
3 μl of the primer/probe mix (Hs01556561_g1 and Hs01
556562_g1; Applied Biosystems, Darmstadt, Germany),
and 2.25 μl of water. No template controls, NTCs, con-
taining water instead of cDNA were included. All reac-
tions were performed in duplicates as follows: initial
denaturation step of 10 min at 95°C, followed by 10 sec
at 95°C and 1 min 30 sec at 60°C for 40 cycles.
For syndecan SDC-3 and SDC-4 detection in placenta
samples, amplification reactions (13 μl) consisted of 1 μl of
cDNA, 6.5 μl of Power SYBR® Green mastermix containing
PCR buffer, dNTPs, MgCL2, and Ampli-Taq DNA polymer-
ase (Life Technologies, Darmstadt, Germany), 3 μl of the
primer mix (SDC-3: Fwd: CGATGATGA ACT GGATGA
CCT C, Rev: CTG TCT CAA TGC CCG ACT, SDC-4:
Fwd: CAG ACG ATG AGG ATG TAG TGG, Rev: GGA
TGG ACA ACT TCA GGG C), 0.5 μl fluorescein and 2 μl
Table 2 Presence of Y-P30/dermcidin transcript in human
PBMCs at different pregnancy stages







NP (n = 16) I 2/16 2/9
NP (n = 2) II 0/2 1/1
NP (n = 6) III 0/6 1/3
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cluded. All reactions were performed in duplicates as fol-
lows: initial denaturation step of 10 min at 95°C, followed by
30 sec at 95°C, 45 sec at 58°C and 30 sec at 72°C for 40 cy-
cles. Fluorescence, and thus quantity of PCR product, was
continuously monitored by iQ5 software (version 2.0 for
Windows, Bio-Rad, Munich, Germany). All samples were
normalized to their β-actin content. Relative expression was
calculated using the formula 2-ΔCT (CT; cycle threshold),
where ΔCT is (gene of interest CT)–(reference gene CT).
Protein isolation and Western blot analysis
For detection of SDC-3, SDC-4 and Y-P30/dermcidin
protein expression, proteins were isolated from frozen
placental tissue pieces as described previously [30] and
their concentration was assessed by using the BCA
Protein Assay (Thermo Fischer Scientific, Bonn, Germany).
For Western blot analysis proteins were separated on a
10% (SDCs) polyacrylamide gel under denaturizing con-
ditions. After electrophoresis proteins were transferred
to PVDF membranes. Membranes were incubated over-
night with the following primary antibodies: polyclonal
goat anti-human SDC-1/3 or polyclonal rabbit anti-human
SDC-2/4 (all from Santa Cruz, Heidelberg, Germany) and
rabbit anti-Y-P30 antibody [1]. After three washing
steps with TBST (TBS with 0.05% Tween) for 5 min
each, the membranes were incubated with an HRP-
conjugated anti-rabbit (Thermo Fisher Scientific, Bonn,
Germany) or biotin-conjugated anti-goat (Dako, Glostrup,
Denmark) antibody diluted 1:500 for 60 min at RT,
followed by an avidin/horseradish peroxidase complex
(Vector Laboratories, Burlinghame, USA). The ß-actin
(Sigma, Steinheim, Germany) served as loading control.
The chemiluminescence signal was generated by using
luminol (Sigma, Steinheim, Germany), 4-hydroxycinnamic
acid (p-coumaric acid; Sigma, Steinheim, Germany), and
hydrogen peroxide (Merck, Darmstadt, Germany). The in-
tensity of the bands was quantified by using the GeneSnap®
Software, Version 4.01c from Syngene.
Statistical analysis
Data obtained for protein and mRNA expression is pre-
sented as medians in graphs showing individual values for
each animal. Analysis of statistical differences among the
groups was performed using the nonparametric Kruskal-
Wallis test. For analyzing differences between two particu-
lar groups the Mann Whitney-U-test was applied. In all
cases, p < 0.05 was considered to be statistical significant.
Results
qPCR to analyze the presence of Y-P30/dermcidin transcript
in human PBMCs yields variable results
Based on previous work [1] we first set out to analyze the
presence of Y-P30/dermcidin mRNA in human blood cellsfrom pregnant and non-pregnant women. We purified
PBMCs and analyzed 24 samples from pregnant women at
different pregnancy stages (16 from the first trimester, 2
from the second trimester and 6 from the third trimester)
and performed nested PCR as well as RT-PCR with Y-P30/
dermcidin specific primers. Of the 24 PBMC samples of
pregnant women, only two from the first trimester showed
a positive result by nested PCR, and one sample each from
the second and third trimester was positive for Y-P30/derm-
cidin expression by RT-PCR (Table 2). Thus, analysis of Y-
P30/dermcidin mRNA expression in a larger sample than
we published earlier [1] gave in most cases negative results.
Moreover, attempts to identify a subpopulation of PBMCs
that express the Y-P30/dermcidin mRNA failed (data not
shown). However, the positive results have to be treated
with caution. Previous work has shown that the mRNA Y-
P30/dermcidin is extremely stable and can be used in foren-
sic medicine for sweat detection [31]. It was also reported
that skin and sweat contaminations result in a transfer of Y-
P30/dermcidin mRNA to clothes, which is still detectable
several days later [31]. Even a handkerchief used to wipe the
eye brow several times within 12 h was contaminated with
Y-P30/dermcidin mRNA [31]. One therefore has to take
into account the possibility of contaminations: trace
amounts of skin-derived transcripts e.g. from the experi-
menter might deliver a positive readout when using very
sensitive PCR methods.
Similar contamination problems might be encountered
with the Y-P30 and dermcidin peptide. Studies have
shown that the peptide can be exhaled in cancer patients
[32], asthma, and also healthy volunteers [18], and is
abundantly present on fingerprints [33]. We could rep-
licate these findings and found intense Y-P30/dermci-
din immunoreactivity with two different antibodies on
human fingerprints, and the antigenicity of the skin-
derived peptides on filter paper was stable for several
days (Figure 3).
In previous work we have shown oligomerization of
the Y-P30 peptide [2], and that oligomers are able to
cluster pleiotrophin of the extracellular matrix and
neuronal membrane-bound syndecans, which are im-
portant for neuronal signaling [2] and the induction of
Figure 3 Y-P30 and dermcidin immunoreactivity is present on human fingerprints. (A + B) Human fingerprints on BA85 nitrocellulose were
stained 2 days after sampling with antibodies against DCD and Y-P30 in A and B, respectively. Immunoreactive material concentrates at the pores
of sweat glands aligned in epidermal ridges. C, fingerprint stained under ommision of the primary antibody against Y-P30. Scale bars = 1 mm.
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performed additional oligomerization and stability assays
with the synthethic Y-P30 peptide under various condi-
tions (Figure 4). As in previous work we found SDS-
resistant multimerization of the synthetic Y-P30 peptide
in the range of 10–15 kDa (Figure 4A). The 10–15 kDa
oligomer species now turned out to be resistant to urea,
DTT and iodoacetamide inclusion in the loading buffer(Figure 4A). Moreover, we found that the 15 kDA oligomer
is stable for at least 14 days. No apparent degradation
was detectable in samples previously kept from 1 to
14 days at room temperature in an Eppendorf tube on a
bench shelf with regular light exposure (Figure 4B).
Thus, the Y-P30 peptide is extremely stable suggesting
that even minor contaminations might last for longer
periods of time.
Figure 4 The Y-P30 peptide is very stable and forms oligomers that migrate at a molecular weight between 10–15 kDa. (A) Oligomers
are highly stable and resistant to SDS and reducing agents added for 2 h or overnight (ON). 10 μg synthetic peptide were loaded in each lane.
(B) Storage of the peptide in solution for up to 14 days at room temperature in an Eppendorf tube on a lab bench does not lead to obvious
degradation of the peptide multimer. 13,5 μg of the peptide were loaded in each lane.
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of first trimester pregnancies
We next followed up on previous reports documenting
the expression of Y-P30 and dermcidin in placenta [20].
We studied this in human samples and found that in
fact Y-P30/dermcidin mRNA was present in human
placenta from the first trimester of normal pregnancies
(n = 8; data not shown). Given the potential pitfalls out-
lined above with mRNA detection, we next analyzed in ly-
sates of human placenta the presence of Y-P30/dermcidin
protein by means of an antibody recognizing the larger
precursor protein containing both, Y-P30 and dermcidin
(Figure 5A). We observed the presence of the precursor
protein (Figure 5A) at two different time points, week 8
and week 12 of pregnancy. There is conflicting evidence
on the size of the Y-P30/Dermcidin precursor in immuno-
blotting. Our data are in accordance with previous studies
[3,10,11,13], who also reported higher molecular weight
bands above 50 kDa when run on a standard reducing
SDS-polyacrylamide gel. Besides oligomerization, glycosyl-
ation and albumin-binding can modify the peptide in tis-
sue and could possibly account for these higher MW
bands [3,10,13]. Further, using a dermcidin ELISA assay,
we could also confirm the presence of dermcidin in pla-
centa extracts (Figure 5B). The levels of dermcidin in
serum and plasma obtained from the same patients
were at the detection limit (Figure 5B). We observed no
lower Y-P30/dermcidin levels in patients suffering from
pre-eclampsia as compared to samples from normally
developing pregnancies (Figure 5C + D). In addition,
administration of the peptide at doses of 100 μg, 250 μg
and 500 μg did not induce pre-eclampsia in mice (unpub-
lished observations) and had also no effect on different
immune cell populations (unpublished observations).
Dermcidin seems to be regulated by various stimuli [34].
To test the hypothesis that hormones synthesized by the
placenta and released to the circulation might evoke anexpression of Y-P30 in cells of the immune system
(PBMCs), we studied the effect of human chorionic go-
nadotropin (hCG), estradiol, progesterone and the com-
bination of the latter two. The effect of alpha-feto-protein
(αFP), which is released by the fetus into the maternal cir-
culation, was also analyzed. We found that estradiol and
progesterone at natural amounts present in the serum
during first trimester as well as the combination of both
hormones did not provoke the expression of Y-P30 in
PBMCs from non-pregnant donors (data not shown). In
addition, also αFP and hCG did not induce Y-P30 expres-
sion (data not shown). Thus, molecules produced by the
placenta or the fetus during early pregnancy seem not re-
sponsible for the occasional presence of Y-P30 transcripts
in immune cells.
Y-P30 binding proteins are expressed in placenta
Since Y-P30 can be detected in placenta, we next investi-
gated whether its binding proteins, syndecans [2] are
expressed in the placenta as well. We indeed found that,
syndecan-3 and syndecan-4 can be found in human pla-
centa at the mRNA (Figure 6A,C) and protein level
(Figure 6B, D). Interestingly, the expression of both syn-
decan proteins was diminished in placentas from patients
suffering from pre-eclampsia as compared to placentas
from patients with normally developing pregnancies
(Figure 6). The presence of pleiotrophin specifically in
human placenta has been reported earlier [35].
Y-P30 is released from HEK-293 T and COS-7 cells together
with the signaling peptide after cleavage from dermcidin
The data so far support a synthesis of Y-P30/dermcidin in
placenta. Similar to sweat glands, the peptides are presum-
ably secreted because both act on cells from the outside.
Y-P30 triggers signaling at the level of the neuronal mem-
brane and the antimicrobial dermcidin peptides kills
bacteria by forming large ion pores in the cell wall [36].
Figure 5 Western blot analysis. (A) The Y-P30/dermcidin precursor peptide is present in placenta at a molecular weight above 50 kDa (arrow).
(B) With an ELISA assay we could also detect dermcidin in placenta extracts. Dermcidin levels in serum and plasma from the same patients were
at the detection limit. (C + D) Y-P30/dermcidin precursor expression in placenta from normal pregnant women (INT, interruptio; TERM, after birth)
and women suffering from pregnancy complications (SA, spontaneous abortion; PE, pre-eclampsia).
Mikhaylova et al. BMC Research Notes 2014, 7:400 Page 8 of 12
http://www.biomedcentral.com/1756-0500/7/400The nature of the secreted peptide species and the mechan-
ism of processing of the precursor are currently only
known in sweat glands for the dermcidin [37,38]. We there-
fore aimed to understand how Y-P30 is secreted from cells.
To this end, we generated GFP-fusion constructs contain-
ing either the whole precursor protein containing the signal
peptide, Y-P30 and dermcidin, only Y-P30 and dermcidin,
Y-P30 and the signal peptide, or Y-P30 alone; all of se-
quences were tagged with GFP (Figure 2A). These con-
structs were transfected into COS-7 and HEK-293 T cells;
both are primate cell lines. The presence of the various
peptide fragments was analyzed by employing an antibody
that recognizes Y-P30 or by an antibody against the GFP
tag in lysates of either the cell pellet or the cell culture
supernatant. We found that the Y-P30 portion of the pre-
cursor becomes secreted from COS-7 and HEK-293 T cells
(Figure 2). The presence of the signal peptide is essential
for secretion and intracellular cleavage removes the dermci-
din part from the precursor molecule (Figure 2B).No evidence for uptake of the Y-P30/dermcidin precursor
Next, we produced and purified large amounts of the full-
length Y-P30/dermcidin GFP- tagged precursor containing
the signal peptide using the Intein expression system [25].
We applied the purified protein at 10 μg/ml medium to dif-
ferentiated primary cortical neurons, and we found the
GFP-fluorescence aggregating at dendritic sites and a pro-
trusions that resemble spines. However, no uptake into the
neurons was apparent (Figure 7).
In a co-culture model where we expressed the signal
peptide containing fusion protein SP-Y-P30-GFP in
HEK-293 T cells, and added these cells to young cortical
primary neurons, we found that although the SP-Y-P30-
GFP protein is secreted from the HEK-293 T cells (see
Figure 2) no uptake of the peptide into the co-cultured
neuronal somata or neurites was visible (Figure 8).
Taken together these data indicate that fragments of the
precursor that contain the signal peptide are not taken
up by neurons.
Figure 7 Administration of bacterially produced and purified GFP (A) or SP-Y-P30-GFP (B) protein to cortical primary neurons does not
result in uptake of the proteins. Cells were stained with a anti-MAP2 antibody to visualize dendritic processes, and with anti-Y-P30 antibody to
detect the peptide. Note in (B) that SP-Y-P30-GFP deposits are always close to neuronal membranes. Scale bars are 20 μm.
Figure 6 Syndecan-3 and −4 expression in placenta. (A + C) mRNA expression, (B + D) Syndecan-3 and −4 protein expression. qPCR and
Western blot analysis show differential expression patterns of syndecan-3 and −4 in human placenta samples from normal pregnant women (INT,
interruptio; TERM, normal pregnancy, tissue sampled after birth) and women suffering from pregnancy complications (SA, spontaneous abortion;
PE, pre-eclampsia). mRNA and proteins were isolated from snap frozen placenta samples. Expression was normalized to the house-keeping gene
beta-actin. Each square represents one sample and data are presented as medians. Statistical differences between two groups were analyzed by
the Mann–Whitney U-test. N.D., non-detectable. **p ≤ 0.01.
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Figure 8 HEK-293 T cells were transfected with different Y-P30-GFP constructs and co-cultured with cortical primary neurons. Of the
constructs tested, SP-Y-P30-GFP has been shown in Figure 2 to deliver a protein detectable in the culture supernatant. However, the peptide is
not taken up into neurons. White arrows point to MAP-2 immunoreactive neurons (blue in the merged picture), purple arrows to transfected
HEK-293 T cells (green or red + green in the merged pictures). Scale bar is 20 μm.
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In this study we followed up on previous work on the
expression and biophysical properties of the survival-
promoting peptide Y-P30. A presence of the Y-P30
peptide in non-human primates has been reported in
proteomic studies as well as by other methods
[1,13,14,23,24,39,40]. However, we and others found
that the peptide is extremely stable and in conjunction
with the stable mRNA [31], a serious pitfall is a contamin-
ation of the samples. Particularly, previous results on the
localization of Y-P30 in rodents are erroneous, because
the dermcidin gene has not been identified in rodents
[12,17]. Given that the Y-P30/dermcidin precursor ispresent in skin, sweat [12] and tears [41] and probably
breath [42,43] the likelihood of contamination is relatively
high. Moreover, antibodies might cross-react with re-
motely related peptides in rodents. We therefore won-
dered how these findings relate to previous data that
suggest expression of Y-P30/dermcidin mRNA in PBMCs
of humans and rodents during pregnancy [1]. In a larger
number of human samples we could not replicate these
previous observations; rather, we found that the presence
of the transcript in PBMCs is variable, and is not related
to pregnancy. Moreover, application of hormones circulat-
ing during pregnancy failed to induce expression of
the Y-P30/dermcidin precursor. Although the problems
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peptides and mRNA outlined above make it difficult to
come to a final conclusion, it seems unlikely that PBMCs
are a source of the Y-P30/dermcidin precursor.
In accord to a previous study [20] we detected Y-P30/
dermcidin immunoreactivity in human placenta with im-
munoblot analysis and ELISA. Dermcidin and Y-P30 have
reportedly substantial proteolytical activity [13,20], and
dermcidin kills bacteria. Therefore, dermcidin could have
local antibiotic effects and protect from infections. Intri-
guingly, a recent study finds a unique microbiome in the
human placenta which has been so far considered to be
sterile [44]. Previous studies as well as the present work
raise the possibility that Y-P30 is expressed in the pla-
centa. Y-P30 might reach the fetus and the fetal brain to
exert neuritogenic activity during development. Indeed,
when injecting a bacterially produced tagged Y-P30 pep-
tide into the maternal circulation, the peptide can be
detected (using anti-tag antibodies) in brain of the off-
spring [2]. We now found that the Y-P30 precursor pep-
tide becomes released from overexpressing non-neural
cells. When the exogenous peptide was added to differen-
tiated neurons, a binding to dendritic sites resembling
spines or spine synapses was observed. Likely this is due
to its affinity for pleiotrophin and syndecans [2], and the
latter trigger the signaling leading to neuritogenic activ-
ities. However, no uptake was observed. Similarly, in the
co-culture experiments we could not detect an uptake
into young neurons in short term cultures. There was also
no aggregation of the peptide to the neuronal membranes
which might be due to the immaturity of the neurons
employed for this assay. Whether the precursor can be
cleaved further by extracellular proteases and whether
shorter fragments of Y-P30 peptide could be taken up by
neurons is at present unclear.
Y-P30 could also act within the placenta or the tropho-
blast. The syndecan binding proteins of Y-P30 are present
in the placenta. The placental syndecan expression levels
were lower in patients suffering from pre-eclampsia. Of
note, syndecan-1 expression was already previously sug-
gested as a risk factor for pre-eclampsia [45]. Pleiotrophin
and syndecans might regulate trophoblast life cycle and
angiogenesis, and intriguingly, the trophoblast expression
of pleiotrophin occurs only in human and higher primates
[32,35]. Signaling of the primate-specific Y-P30 peptide
might be involved in these processes.
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